4D Molecular director granted 50,000 stock options
4D Molecular Therapeutics director Charles Theuer received a grant of stock options for 50,000 shares of common stock as part of non-employee director compensation.
Rhea-AI Filing Summary
4D Molecular Therapeutics director Charles Theuer received a grant of stock options for 50,000 shares of common stock as part of non-employee director compensation. The options have an exercise price of $9.42 per share and expire on June 16, 2036.
One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until full vesting on June 17, 2029, contingent on continued service. The options also vest in full if a Change in Control, as defined in the 2020 Incentive Award Plan, is completed.
Insider Trade Summary
Grant/Award: 50,000 shares
Grant/Award
1 txn
Insider
THEUER CHARLES
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,000 contracts (Direct)
Footnotes (2)
- F1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- F2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Key Figures
Option grant size: 50,000 options
Exercise price: $9.42 per share
Expiration date: June 16, 2036
+3 more
6 metrics
Option grant size
50,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$9.42 per share
Conversion or exercise price of granted options
Expiration date
June 16, 2036
Option term end date
Shares underlying options
50,000 shares
Common Stock underlying the derivative security
Initial cliff vesting date
June 17, 2027
1/3 of options vest on this date
Full vesting date
June 17, 2029
All options fully vested by this date
Key Terms
Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
non-employee director compensation program financial
"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."
Change in Control financial
"Additionally, the stock options will vest in full upon the consummation of a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2020 Incentive Award Plan financial
"Change in Control (as defined in the 2020 Incentive Award Plan)."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FDMT director Charles Theuer report in this Form 4 filing?
Charles Theuer reported receiving a grant of stock options for 50,000 shares of 4D Molecular Therapeutics common stock. These options were automatically granted under the company’s non-employee director compensation program as part of his board service compensation package.
What is the exercise price and term of the new FDMT stock options?
The granted stock options have an exercise price of $9.42 per share and expire on June 16, 2036. This means Theuer can buy shares at $9.42 once vested, any time before the June 2036 expiration date, subject to plan and service conditions.
How do the FDMT options granted to Charles Theuer vest over time?
One-third of the 50,000 options vest on June 17, 2027, with the remaining two-thirds vesting in equal monthly installments thereafter. Vesting continues until all options are fully vested on June 17, 2029, assuming Theuer continues serving the company through each vesting date.
Is there any accelerated vesting feature for these FDMT stock options?
Yes. The stock options will vest in full upon the consummation of a Change in Control, as defined in 4D Molecular Therapeutics’ 2020 Incentive Award Plan. This provision accelerates vesting if the company undergoes a qualifying acquisition or similar control transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
